HC Wainwright Maintains Black Diamond Therapeutics Price Target at $11
HC Wainwright & Co. maintained its $11.00-per-share price target for Black Diamond Therapeutics.
Related stories
WY Reports FY2026 Third-Quarter Profit
Profit attributable to shareholders rose 51.6% year over year. Basic earnings per share was also reported.
M impact | EQUITY | Oct 30, 2026, 06:51 AM UTC
KOSPI Falls More Than 3% as AI Profitability Worries and Foreign Selling Weigh
The KOSPI fell more than 3% at the close, with AI profitability concerns and foreign selling cited; the index was down 16% for the month.
M impact | EQUITY | Oct 30, 2026, 06:43 AM UTC
Amazon Reports Fiscal Q3 Profit of 1136亿美元, Up 101.12%
Amazon reported fiscal third-quarter profit attributable to shareholders of 1136亿美元, up 101.12% year over year, with basic EPS of 10.55美元.
M impact | EQUITY | Oct 30, 2026, 06:43 AM UTC
Intel Shares Plunge 23% on Production Bottlenecks, Negative FCF Outlook
H impact | EQUITY | Oct 30, 2026, 06:42 AM UTC
Q-linea Q3 Sales Rise, Signs US Healthcare Agreement
Swedish healthcare company Q-linea reported higher third-quarter sales and a new US healthcare agreement.
M impact | EQUITY | Oct 30, 2026, 06:42 AM UTC
Loomis Q3 Revenue Slightly Misses Estimates
Sweden's Loomis reported Q3 revenue slightly below estimates.
M impact | EQUITY | Oct 30, 2026, 06:42 AM UTC